KR20240015729A - 스미스 마제니스 증후군을 치료하기 위한 타시멜테온 - Google Patents

스미스 마제니스 증후군을 치료하기 위한 타시멜테온 Download PDF

Info

Publication number
KR20240015729A
KR20240015729A KR1020247002426A KR20247002426A KR20240015729A KR 20240015729 A KR20240015729 A KR 20240015729A KR 1020247002426 A KR1020247002426 A KR 1020247002426A KR 20247002426 A KR20247002426 A KR 20247002426A KR 20240015729 A KR20240015729 A KR 20240015729A
Authority
KR
South Korea
Prior art keywords
individual
clause
melatonin
tasimelteon
sleep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247002426A
Other languages
English (en)
Korean (ko)
Inventor
크리스챤 레이브단
미하엘 에이치. 폴리메로폴로스
Original Assignee
반다 파마슈티칼즈, 인코퍼레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54147267&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20240015729(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 반다 파마슈티칼즈, 인코퍼레이티드. filed Critical 반다 파마슈티칼즈, 인코퍼레이티드.
Publication of KR20240015729A publication Critical patent/KR20240015729A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electric Connection Of Electric Components To Printed Circuits (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Processing Of Solid Wastes (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coils Or Transformers For Communication (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Led Device Packages (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
KR1020247002426A 2014-09-02 2015-08-29 스미스 마제니스 증후군을 치료하기 위한 타시멜테온 Pending KR20240015729A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462044856P 2014-09-02 2014-09-02
US62/044,856 2014-09-02
US201562169635P 2015-06-02 2015-06-02
US62/169,635 2015-06-02
KR1020177009052A KR20170048541A (ko) 2014-09-02 2015-08-29 스미스 마제니스 증후군을 치료하기 위한 타시멜테온
PCT/US2015/047610 WO2016036619A1 (en) 2014-09-02 2015-08-29 Tasimelteon for treating smith-magenis syndrome

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177009052A Division KR20170048541A (ko) 2014-09-02 2015-08-29 스미스 마제니스 증후군을 치료하기 위한 타시멜테온

Publications (1)

Publication Number Publication Date
KR20240015729A true KR20240015729A (ko) 2024-02-05

Family

ID=54147267

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247002426A Pending KR20240015729A (ko) 2014-09-02 2015-08-29 스미스 마제니스 증후군을 치료하기 위한 타시멜테온
KR1020177009052A Ceased KR20170048541A (ko) 2014-09-02 2015-08-29 스미스 마제니스 증후군을 치료하기 위한 타시멜테온

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177009052A Ceased KR20170048541A (ko) 2014-09-02 2015-08-29 스미스 마제니스 증후군을 치료하기 위한 타시멜테온

Country Status (17)

Country Link
US (5) US10179119B2 (enExample)
EP (2) EP4137129A1 (enExample)
JP (3) JP6903571B2 (enExample)
KR (2) KR20240015729A (enExample)
CN (2) CN116098887A (enExample)
AU (2) AU2015312252B2 (enExample)
BR (1) BR112017003644A2 (enExample)
CA (2) CA3124872A1 (enExample)
DK (1) DK3188727T3 (enExample)
ES (1) ES2936833T3 (enExample)
FI (1) FI3188727T3 (enExample)
HR (1) HRP20230070T1 (enExample)
HU (1) HUE061051T2 (enExample)
MX (1) MX386150B (enExample)
PT (1) PT3188727T (enExample)
SI (1) SI3188727T1 (enExample)
WO (1) WO2016036619A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2488392C2 (ru) * 2006-05-22 2013-07-27 Ванда Фармасьютиклз, Инк. Лечение агонистом мелатонина
SI3188727T1 (sl) * 2014-09-02 2023-03-31 Vanda Pharmaceuticals Inc. Tasimelteon za zdravljenje Smith-Magenisovega sindroma
BR112020017886A2 (pt) * 2018-03-04 2021-03-23 Vanda Pharmaceuticals Inc. métodos para tratar um indivíduo experienciando um avanço na interrupção do ciclo de dormir-despertar na hora de dormir estabelecida do indivíduo, para tratar jet lag em um indivíduo e para reduzir uma consequência indesejada de um avanço de até oito horas em uma hora de dormir estabelecida do indivíduo, e, unidade de dispensação pré-empacotada
WO2020056117A1 (en) * 2018-09-12 2020-03-19 Vanda Pharmaceuticals Inc.. Improving sleep or post-sleep performance
JP7503632B2 (ja) 2019-12-13 2024-06-20 バンダ・ファーマシューティカルズ・インコーポレイテッド 液体タシメルテオン製剤及びそれを使用する方法
JP7628127B2 (ja) 2020-08-27 2025-02-07 株式会社ヨコオ 検査装置
AU2022345260A1 (en) * 2021-09-14 2024-04-04 Vanda Pharmaceuticals Inc. Treatment of sleep disturbances in autism spectrum disorder patients

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856529A (en) 1996-12-10 1999-01-05 Bristol-Myers Squibb Company Benzofuran and dihydrobenzofuran melatonergic agents
KR20090105333A (ko) 2008-04-02 2009-10-07 주식회사 동부하이텍 데이터 수신 장치

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050137247A1 (en) 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
US7754902B2 (en) 2006-05-18 2010-07-13 Vanda Pharmaceuticals, Inc. Ruthenium(II) catalysts for use in stereoselective cyclopropanations
RU2488392C2 (ru) 2006-05-22 2013-07-27 Ванда Фармасьютиклз, Инк. Лечение агонистом мелатонина
US20080260837A1 (en) 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
WO2011009102A1 (en) 2009-07-16 2011-01-20 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
KR102171965B1 (ko) * 2012-01-26 2020-10-30 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
CN102675268A (zh) * 2012-05-18 2012-09-19 济南志合医药科技有限公司 制备（1r，2r）-2-（2,3-二氢苯并呋喃-4-基）环丙甲胺的方法
US10376487B2 (en) * 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
SI3188727T1 (sl) * 2014-09-02 2023-03-31 Vanda Pharmaceuticals Inc. Tasimelteon za zdravljenje Smith-Magenisovega sindroma
JP7503632B2 (ja) * 2019-12-13 2024-06-20 バンダ・ファーマシューティカルズ・インコーポレイテッド 液体タシメルテオン製剤及びそれを使用する方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856529A (en) 1996-12-10 1999-01-05 Bristol-Myers Squibb Company Benzofuran and dihydrobenzofuran melatonergic agents
KR20090105333A (ko) 2008-04-02 2009-10-07 주식회사 동부하이텍 데이터 수신 장치

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Neuropsychiatric Disease and Treatment, Vol. 5, pp. 341-354 (2009)

Also Published As

Publication number Publication date
US10179119B2 (en) 2019-01-15
HRP20230070T1 (hr) 2023-03-17
CA2957588C (en) 2021-08-31
JP2017526693A (ja) 2017-09-14
EP3188727A1 (en) 2017-07-12
EP3188727B1 (en) 2022-11-09
EP4137129A1 (en) 2023-02-22
FI3188727T3 (fi) 2023-02-20
KR20170048541A (ko) 2017-05-08
JP7132277B2 (ja) 2022-09-06
ES2936833T3 (es) 2023-03-22
US20220133681A1 (en) 2022-05-05
US20240293355A1 (en) 2024-09-05
CN106604726A (zh) 2017-04-26
AU2015312252B2 (en) 2020-07-02
JP6903571B2 (ja) 2021-07-14
US20190105297A1 (en) 2019-04-11
JP7252390B2 (ja) 2023-04-04
PT3188727T (pt) 2023-01-30
JP2022078291A (ja) 2022-05-24
MX386150B (es) 2025-03-18
US10653665B2 (en) 2020-05-19
MX2017002796A (es) 2017-06-09
CN116098887A (zh) 2023-05-12
SI3188727T1 (sl) 2023-03-31
AU2015312252A1 (en) 2017-03-30
AU2020239640A1 (en) 2020-10-15
HUE061051T2 (hu) 2023-05-28
US11266622B2 (en) 2022-03-08
CA2957588A1 (en) 2016-03-10
NZ765911A (en) 2023-08-25
NZ729901A (en) 2020-09-25
US20200237712A1 (en) 2020-07-30
US20170239210A1 (en) 2017-08-24
CA3124872A1 (en) 2016-03-10
DK3188727T3 (da) 2023-02-06
JP2020143159A (ja) 2020-09-10
BR112017003644A2 (pt) 2017-11-28
WO2016036619A1 (en) 2016-03-10
AU2020239640B2 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
US20240293355A1 (en) Method of treatment
EA015256B1 (ru) Производные тетрагидроизохинолина для повышения функции памяти
US20250352540A1 (en) Uses of a pure 5-ht6 receptor antagonist
US20140163050A1 (en) Use of 1H-quinazoline-2,4-diones
NZ729901B2 (en) Tasimelteon for treating smith-magenis syndrome
NZ765911B2 (en) Tasimelteon for treating smith-magenis syndrome
AU2011376333A1 (en) Use of 1H-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy
CN114761008B (zh) 用于在患有痴呆的患者中治疗行为和心理症状的方法
TW202515540A (zh) 使用三重再攝取抑制劑治療睡眠障礙之方法

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902